Organization
Centocor R&D, Inc, New Jersey, United States
2 abstracts
Abstract
AN IMMEDIATE DECREASE IN SERUM-VEGF-LEVELS HELPS IN PREDICTING A MAJOR RESPONSE IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO WERE STARTED ON INFLIXIMAB: RESULTS FROM THE ASSERT BIOMARKER STUDY Org: Rheumazentrum Ruhrgebiet, Herne, Germany, University Medical Center, Maastricht, University Medical Center, Amsterdam, Netherlands, Centocor R&D, Inc, New Jersey, United States, University Medical Center, Leiden, Netherlands,
Abstract
A BIOMARKER RESPONSE IS NOT ASSOCIATED WITH LONG-TERM RADIOGRAPHIC PROGRESSION IN AS PATIENTS TREATED WITH INFLIXIMAB: A FOLLOW-UP EVALUATION OF THE ASSERT BIOMARKER STUDY Org: Rheumazentrum Ruhrgebiet, Herne, Germany, University Medical Center, Maastricht, University Medical Center, Amsterdam, University Medical Center, Leiden, Netherlands, German Rheumatism Research Center, Berlin, Germany,